Keyword Search Year None202120202019201820172016201520142013201220112010200920082007200620052004200320022001 06/22/21 Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign 06/04/21 Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting 06/03/21 Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference 06/01/21 Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder 05/28/21 Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting 05/20/21 Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors 05/13/21 Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer 05/05/21 Alkermes to Take Part in the BofA Securities 2021 Virtual Healthcare Conference 05/03/21 Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month 04/30/21 Alkermes Announces Agreement with Sarissa Capital 04/28/21 Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting 04/28/21 Alkermes plc Reports First Quarter 2021 Financial Results 04/27/21 Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence 04/27/21 Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma 04/21/21 Alkermes to Host Conference Call to Discuss First Quarter 2021 Financial Results 04/20/21 Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society 04/07/21 Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer 03/25/21 Alkermes to Take Part in Stifel's 3rd Annual CNS Day 03/25/21 Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy 03/11/21 Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma 03/04/21 Alkermes to Hold Virtual Investor Day 02/18/21 Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference 02/11/21 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021 02/04/21 Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results 01/14/21 NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine 01/06/21 Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference 01/06/21 Alkermes Announces Updates to Executive Leadership Team
06/22/21 Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign
06/04/21 Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
06/01/21 Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
05/28/21 Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
05/13/21 Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
05/03/21 Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month
04/28/21 Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting
04/27/21 Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma
04/20/21 Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society
04/07/21 Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer
03/11/21 Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
02/11/21 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021
02/04/21 Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
01/14/21 NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
